Compare Revvity Inc (RVTY) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs BlackRock TCP Capital Corp — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while BlackRock TCP Capital Corp trades at $3.9 (market cap $327.64M). The key difference: Revvity Inc is far larger — about 39.4× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (19.46%). Which is the better fit depends on your goals.
| RVTY | TCPC | |
|---|---|---|
Market Cap | $12.91B | $327.64M |
Sector | Technology | Financials |
52-Week High | $117.75 | $7.26 |
52-Week Low | $82.26 | $3.13 |
Enterprise Value | $15.23B | — |
Dividend Yield | 0.24% | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
TCPC trades at $4.00, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a low P/B of 0.59 suggesting potential undervaluation amid financial challenges.
The outlook is mixed: strategic actions and dividend yield near 8.5% offer value, but persistent losses, class action lawsuits, and high P/S ratio pose significant risks. Analyst consensus is cautious with more holds than buys, reflecting uncertainty over the company's turnaround efforts and profitability path.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
